Neutralizing antibodies in multiple sclerosis: A complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes

Multiple Sclerosis

Volumn 13, Issue SUPPL. 1, 2007, Pages

  Reder, Anthony T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Binding antibody; Interferon receptone; Interferon ; Multiple sclerosis; Neutralizing antibody

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INSULIN; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEOPTERIN; NEUTRALIZING ANTIBODY; PLACEBO;

ANEMIA; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CORRELATION FUNCTION; CYTOPATHOGENIC EFFECT; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE APLASIA; HUMAN; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN INDUCTION; RADIOIMMUNOPRECIPITATION; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34250637535     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507076992     Document Type: Article

References (36)

1. Hemmer B, Stuve O, Kieseier B, Schellekens H, Hartung H-P. Immune response to immunotherapy the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005; 4 403-411.
2. Hartung HP, Munschauer F III, Schellkens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 2005; 12: 588-601.
3. Knobler RL, Greenstein JI, Johnson KP et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993; 13: 333-40.
4. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706-12.
5. Bertolotto A, Malucchi S, Sala A et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73: 148-53.
6. Scagnolari C, Bellomi F, Turriziani O et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002; 22: 207-13.
7. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
8. Herndon RM, Rudick RA, Munschauer FE III et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409-19.
9. Petkau AJ, White R, Ebers GC, Reder AT, Sibley WA, Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10:126-38.
10. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95-100.
11. Reder AT. Multiple sclerosis. In Gilman S, Goldstein GW, Waxman SG eds. Neurobase, Medlink Neurology. Arbor Publishing, 2007.
12. Barbosa MDF Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 2006; 118: 42-50.
13. Oger J, Kastrukoff L, O'Gorman M, Paty DW. Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations. J Neuroimmunol 1986; 12: 37-48.
14. Oger JJF Vorobeychick G, Al-Fahim A, Aziz T, Paty D. Neutralizing antibodies in betaseron-treated MS patients and in vitro immune function before treatment. Neurology 48: 1997; abstract.
15. Reder A, Vellichko S, Wagner C, Yamaguchi K, Salamon H, Stuerzebecher C et al. Betaseron pharmacogenomics studies: Gene expression profiling in healthy individuals and relapsing-remitting multiple sclerosis patients after a single dose of betaseron. Mult Scler 2005; 10(Suppl 2): Abstract p434.
16. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002; 129: 105-115.
17. Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997; 48: 1446-48.
18. Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6: 86-90.
19. Francis GS, Rice GP, Alsop JC, Group PPoRaDblb-aSiMSS. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
20. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13.
21. Sibley WA, The IFN-Beta Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis withinterferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
22. Polman C, Kappos L, White R et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37-43.
23. Rudick RA, Simonian NA, Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-72.
24. Kappos L, Clanet M, Sandberg-Wollheim M et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
25. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
26. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
27. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59: 1496-506.
28. Giovannoni G, Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005; 65: 6-8.
29. Arnason BG, Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies. J Interferon Cytokine Res 1998; 18: 639-44.
30. White DM, Jensen MA, Shi X, Qu Zx, Arnason BG. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcγ receptors. Protein Expr Purif 2001; 21: 446-455.
31. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J et al. Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol Cell Biol 2006; 26: 1888-1897.
32. Prlic M, Bevan MJ. Immunology. An antibody paradox, resolved. Science 2006; 311: 1875-76.
33. Shapiro AM, Jack CS, Lapierre Y, Arbour N, Bar-Or A. Antel JP. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Arch Neurol 2006; 63: 1296-99.
34. Hurwitz B, Polman CH. Neutralizing antibodies to interferon beta-1b: real-world data. Mult Scler 2003; 9(Suppl): S40,
35. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
36. Durelli L, Torino, Verdun E, Barbera P, Bergui M, Pipieri A et al. The OPTimization of interferon for MS (OPTIMS) study. A multicenter trial comparing two different doses (250 and 375 mcg) of IFN beta-1b. Neurology 2004; 62(Suppl 5): Abstract A153.